Literature DB >> 6413261

Pulsatile subcutaneous low-dose gonadotropin-releasing hormone treatment of anovulatory infertility.

G Skarin, S J Nillius, L Wide.   

Abstract

Subcutaneous pulsatile long-term administration of low doses of gonadotropin-releasing hormone (GnRH) was given for induction of ovulation to 14 infertile amenorrheic women who did not respond to clomiphene citrate. A small peristaltic pump was used to deliver 1, 5, or 20 micrograms of GnRH every 90 minutes. Nineteen treatment courses with a duration of 26 to 187 days were given. Thirty-six ovulatory cycles were induced in 12 of the 14 women; 8 of the women conceived. Five healthy children have been born. Three early spontaneous abortions occurred. The subcutaneous GnRH therapy was given with the same pulse frequency until menstruation or pregnancy occurred. The treatment could be given without interruption to induce repeated ovulatory menstrual cycles. No serious adverse effects occurred. Subcutaneous pulsatile administration of low doses of GnRH is a promising new treatment of women with anovulatory infertility.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6413261     DOI: 10.1016/s0015-0282(16)47353-x

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  3 in total

Review 1.  [Pulsatile therapy with LHRH].

Authors:  M H Birkhäuser
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

2.  Injection sites and pharmacokinetics of luteinizing hormone releasing hormone: comparison of two different subcutaneous administration routes.

Authors:  R Torre; L Traverso; P Cavagnaro; M Giusti; G Giordano
Journal:  J Endocrinol Invest       Date:  1989-10       Impact factor: 4.256

3.  Pulsatile luteinizing hormone releasing hormone treatment for induction of ovulation. Radioimmunoassay of plasma LHRH and comparative study of subcutaneous versus intravenous routes of administration.

Authors:  B Couzinet; N Lahlou; N Lestrat; P Bouchard; M Roger; G Schaison
Journal:  J Endocrinol Invest       Date:  1986-04       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.